ANIX
Anixa Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.07
+0.66%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | 210.0K | — |
| Cost of Revenue | 9.0K | 36.0K | — | 161.0K | — |
| Gross Profit | (9.0K) | (36.0K) | — | 49.0K | — |
| Operating Expenses | |||||
| R&D Expense | 4.6M | 5.1M | 6.4M | 4.8M | 6.7M |
| SG&A Expense | 6.1M | 6.6M | 7.4M | 6.3M | 7.2M |
| General & Admin Expense | 6.1M | 6.6M | 7.4M | 6.3M | 7.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (9.0K) | (36.0K) | — | — | — |
| Total Operating Expenses | 10.7M | 11.7M | 13.8M | 11.1M | 13.9M |
| Cost and Expenses | 10.7M | 11.7M | 13.8M | 11.2M | 13.9M |
| Operating Income (EBIT) | (10.7M) | (11.7M) | (13.8M) | (11.0M) | (13.9M) |
| Non-Operating | |||||
| Interest Income | 552.0K | 673.0K | 1.1M | 1.1M | 104.0K |
| Interest Expense | — | — | — | — | 104.0K |
| Net Interest Income | 552.0K | 673.0K | 1.1M | 1.1M | — |
| Other Non-Op Income/Expense | 552.0K | 673.0K | 1.1M | 1.1M | 104.0K |
| Non-Operating Income (excl Interest) | (552.0K) | (673.0K) | (1.1M) | (1.1M) | (104.0K) |
| EBT (Pre-Tax Income) | (10.1M) | (11.0M) | (12.7M) | (9.9M) | (13.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (10.1M) | (10.9M) | (12.6M) | (9.8M) | (13.6M) |
| Earnings from Cont. Ops | (10.1M) | (11.0M) | (12.7M) | (9.9M) | (13.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (10.1M) | (10.9M) | (12.6M) | (9.8M) | (13.6M) |
| Per Share | |||||
| Basic EPS | ($0.30) | ($0.34) | ($0.39) | ($0.32) | ($0.45) |
| Diluted EPS | ($0.30) | ($0.34) | ($0.39) | ($0.32) | ($0.45) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.01 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 33.6M | 32.5M | 31.9M | 31.0M | 30.4M |
| Diluted Shares Outstanding | 33.6M | 32.5M | 31.9M | 31.0M | 30.4M |
| Profitability Metrics | |||||
| EBITDA | (10.1M) | (11.0M) | (12.7M) | (9.9M) | (13.7M) |
| D&A | 28.0K | 36.0K | 37.0K | 46.0K | 42.0K |
| EBIT | (10.1M) | (11.0M) | (12.7M) | (9.9M) | (13.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Apr 1, 2026